Vertex Pharmaceuticals

Open: 329.82 Close: 325.3 Change: -4.52

Our AI found unexpected things about Vertex Pharmaceuticals Stock.

Are looking for the most relevant information about Vertex Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Vertex Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, company, develop, medicine, price, Q1, and the most common words in the summary are: vertex, pharmaceutical, stock, market, party, night, company, . One of the sentences in the summary was: The call contract at the $335.00 strike price has a current …

Concept Map

Semantic Network

Stock Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with.

Today's Summary

15 analysts rated Vertex Pharmaceuticals over the past 3 months. 15 analysts have an average price target of $367.13 versus the current price of Vertex. The call contract at the $335.00 strike price has a current bid of $7.30.30.

Today's News

15 analysts rated Vertex Pharmaceuticals over the past 3 months. Global Amblyopia Market Size was valued at USD 4.6 billion in 2022 and the Worldwide Amblyopic Market size is expected to reach USD 7.9 billion by 2032. Vertex Pharmaceuticals (VRTX) is a biopharma company focused on the development and commercialization of transformative specialty medicines for the treatment of cystic fibrosis (CF) and other rare genetic diseases. 15 analysts have an average price target of $367.13 versus the current price of Vertex. Vertex Pharmaceuticals Incorporated v. Aurobindo Pharma Limited et al 1:2023cv00582 | US District Court for the District of Delaware. The call contract at the $335.00 strike price has a current bid of $7.30.30. Vertex Pharmaceuticals ( NASDAQ:VRTX – Get Rating ) is a global biotechnology company, which engages in the business of discovering, developing, and commercializing innovative medicines. The company has an impressive track record of developing breakthrough treatments. Vertex Pharmaceuticals Inc. is a biopharmaceutical company based in Boston, Massachusetts. It was founded in 1989 by Joshua Boger with the goal of discovering, developing, and commercializing innovative medicines for severe and life-threatening diseases. The company is known for developing revolutionary drugs for cystic fibrosis, which has been a significant achievement. Vertex Pharmaceuticals Inc. hits record high on strong Q1 Earnings. Q1 Profit Decreases, but beats estimates Nasdaq Vertex: Q1 earnings Snapshot.

Stock Profile

"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."

Keywords

This document will help you to evaluate Vertex Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, company, develop, medicine, price, Q1, and the most common words in the summary are: vertex, pharmaceutical, stock, market, party, night, company, . One of the sentences in the summary was: The call contract at the $335.00 strike price has a current bid of $7.30.30.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vertex #pharmaceutical #stock #market #party #night #company.